Impact of circulating tumor DNA (ctDNA) mutant allele fraction in response to anti-angiogenic therapy in RAS-mutant metastatic colorectal cancer (mCRC): Clinical data in the first-line setting and correlation in patient-derived xenograft (PDX) models.

Authors

null

Nadia Saoudi Gonzalez

Medical Oncology Department, Vall d´Hebron University Hospital, Barcelona, Spain

Nadia Saoudi Gonzalez , Javier Ros Montañá , Giulia Martini , Raquel Comas , Ariadna Garcia , Iosune Baraibar , Francesc Salva , Cabellos Laia , Gloria Castillo , Victor Navarro Garces , Raquel Perez-Lopez , Hector G. Palmer , Ana Vivancos , Josep Tabernero , Elena Elez

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3560)

DOI

10.1200/JCO.2022.40.16_suppl.3560

Abstract #

3560

Poster Bd #

354

Abstract Disclosures

Similar Posters

First Author: Nieves Martinez Lago

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Myostatin/activin pathway gene expression and single nucleotide polymorphisms (SNPs) in metastatic colorectal cancer (mCRC).

Myostatin/activin pathway gene expression and single nucleotide polymorphisms (SNPs) in metastatic colorectal cancer (mCRC).

First Author: Karam Ashouri

First Author: Eleonora Lai